In the Pipeline
Our Pipeline at a Glance as of April 1, 2017
Compounds in Development
We are transforming the way serious diseases are treated. Our pipeline currently has 37 compounds in development, focused on key therapeutic areas.
In the Pipeline
Generic Name /
Genetically Defined Diseases assets, Anti-Myostatin and Anti-eTau, were out-licensed on April 13.
* Virology assets removed with sale of virology R&D pipeline to ViiV Healthcare on Feb 22. Bristol-Myers Squibb continues development for HCV assets including Daklinza, Sunvepra and beclabuvir (NS5B Non Nuc) in select markets.
Phase I – clinical trials investigating safety of an investigational medicine in a small number of human subjects.
Phase II – clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.
Phase III – clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.
Marketed Product Development – clinical trials investigating new uses or formulations regarding medicines that have already received regulatory approval for at least one indication in a major market.
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.